Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

47
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
47
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

21
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
21
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.9K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.9K
Antibiotic Selection00:57

Antibiotic Selection

62.0K
Overview
62.0K
Production of Antibiotics01:27

Production of Antibiotics

22
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
22
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.3K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripherally inserted central catheters: a hidden emerging cause of infection outbreaks.

New microbes and new infections·2020
Same author

Investigations by the Institut Hospitalo-Universitaire Méditerranée Infection of food and food-borne infections in the Mediterranean Basin and in sub-Saharan Africa.

New microbes and new infections·2018
Same author

Are we living in an antibiotic resistance nightmare?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Using MALDI-TOF MS typing method to decipher outbreak: the case of Staphylococcus saprophyticus causing urinary tract infections (UTIs) in Marseille, France.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Compared lethality rates of Clostridium difficile infections at the local, regional and national levels in France.

New microbes and new infections·2016
Same author

Citrobacter amalonaticus human urinary tract infections, Marseille, France.

New microbes and new infections·2016
Same journal

Impact of low-dose chest CT and multiplex PCR on antibiotic usage for community-acquired pneumonia: multicentre prospective controlled before-after study with cluster randomisation (CAP-NEXT study).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Clinical Microbiology and Infection: how did we do in 2025?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Automate the work, not the decision: aligning expectations for AI in clinical microbiology.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Doxycycline prophylaxis and gonococcal resistance: reassurance, residual signals, and the case for surveillance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Oral metronidazole versus clindamycin to treat bacterial vaginosis in pregnancies at risk for preterm labor.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Efficacy and safety of a radiographic severity-stratified all-oral short treatment regimen for multidrug/rifampicin-resistant tuberculosis in China: An open-label, multi-center,randomized controlled, non-inferiority trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
See all related articles

Related Experiment Video

Updated: Mar 23, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.8K

Do we need new antibiotics?

J-M Rolain1, C Abat1, M-T Jimeno1

  • 1URMITE UM 63 CNRS 7278 IRD 198 INSERM U1905, IHU Méditerranée Infection, Faculty of Medicine and Pharmacy, Aix-Marseille University, Marseille, France.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|March 30, 2016
PubMed
Summary
This summary is machine-generated.

Antibiotic resistance is not increasing globally as widely reported. Existing antibiotics are effective against most multidrug-resistant (MDR) bacteria, challenging claims of untreatable infections.

Keywords:
Antimicrobial resistanceold antibiotics

More Related Videos

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
05:57

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays

Published on: April 26, 2024

1.4K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K

Related Experiment Videos

Last Updated: Mar 23, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.8K
Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
05:57

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays

Published on: April 26, 2024

1.4K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K

Area of Science:

  • Microbiology and Infectious Diseases
  • Antimicrobial Resistance Surveillance
  • Public Health Policy

Background:

  • Widespread media and scientific reports suggest a global increase in antibiotic resistance, particularly concerning multidrug-resistant (MDR) bacteria.
  • Concerns exist regarding the potential for untreatable infections and high mortality rates associated with MDR bacterial strains worldwide.
  • The development of new antibiotics is frequently cited as a critical need in response to escalating resistance.

Purpose of the Study:

  • To critically evaluate the reality of pandrug-resistant bacteria and the global increase in antibiotic resistance.
  • To examine the purported link between antibiotic resistance and patient mortality.
  • To assess the necessity for developing novel antibiotics in light of current therapeutic options.

Main Methods:

  • Review and synthesis of available data on antibiotic resistance patterns, focusing on European surveillance data for key invasive bacteria.
  • Analysis of clinical outcomes and mortality rates in patients infected with MDR versus non-MDR bacteria.
  • Evaluation of the efficacy of existing antibiotic classes, including older agents, against contemporary resistant bacterial phenotypes.

Main Results:

  • European data indicate that, excluding *Klebsiella pneumoniae* in specific countries, resistance to three or more antibiotic classes (MDR phenotype) has been low and stable over five years.
  • Therapeutic options remain available for both reference and older antibiotics against prevalent resistant bacteria.
  • The clinical impact and attributable mortality of MDR bacterial infections are subjects of ongoing debate and remain controversial.

Conclusions:

  • The current arsenal of available antibiotics, including older ones, appears sufficient to manage emerging bacterial resistance.
  • The notion of widespread untreatable infections due to MDR bacteria may be overstated.
  • Existing antibiotic resources should be preserved as a 'World Heritage' and managed through a non-profit, internationally regulated model.